Compositions and method for protecting skin from UV induced immunosuppression and skin damage

Abstract

A method for protecting skin from either UV-induced immunosuppression or from UV-induced skin damage comprising the topical administration of a composition containing an extract of soy or clover, and/or the isoflavone compounds genistein, biochanin, dihydro-daidzein, diadzein, formonentin, dihydro-geneistein, 2-dehydro-O-desmethyl-angolensin, tetrahydro-daidzein, equol, dehydro-equol, O-desmethyl-angolensin, or 6-hydroxy-O-desmethyl-angolensin. The invention also comprises compositions containing these compounds.

1 - 9 . (Canceled)  
     
     
         10 . A process for the manufacture of a medicament for the treatment, amelioration, prophylaxis and/or prevention of UV induced immunosuppression in the skin, and UV induced skin disorders, which process comprises providing a compound of Formula I:  
       
         
           
           
               
               
           
         
       
       in which 
 Z is H,  
 R 1  is H, or R A CO where R A  is C 1-10  alkyl or an amino acid,  
 R 2  is H, OH, or OR B  where R B  is an amino acid or COR A  where R A  is as previously defined,  
 W is H, A is H or OH, and B is selected from  
                     
 W is H, and A and B taken together form a six membered ring selected from  
                     
 W, A, and B taken with the groups with which they are associated comprise  
                     
 W and A taken together with the groups with which they are associated comprise  
                     
 and B is  
                     
 wherein  
 R 3  is H, COR A  where R A  is as previously defined, CO 2 R C  where R C  is C 1-10  alkyl, or COR B  where R B  is as previously defined,  
 R 4  is H, COR D  where R D  is H, OH, C 1-10  alkyl or an amino acid, CO 2 R C  where R C  is as previously defined, COR E  where R E  is H, C 1-10  alkyl or an amino acid, COOH, COR C  where R C  is as previously defined, or CONHR E  where R E  is as previously defined,  
 R 5  is H, CO 2 R C  where R C  is as previously defined, or COR C OR E  where R C  and R E  are as previously defined, and with the proviso that when the two R 5  groups are attached to the same group, they are identical or different,  
 R 6  is H or hydroxy C 1-10  alkyl,  
 X is O, N or S, and  
 Y is  
                     
 where R 7  is H, or C 1-10  alkyl,  
 and blending said compound with one or more dermatologically acceptable carriers so as to provide a dermatologically acceptable composition.  
 
     
     
         11 . A process according to claim  1  wherein the compound of Formula I is selected from:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       wherein 
 R 7  is H or CH 3 ,  
 R 8  is COR D  where R D  is as previously defined, or H,  
 R 9  is CO 2 R C  or COR E  where R C  and R E  are as previously defined,  
 R 10  is COR C  or COR C OR E  where R C  and R E  are as previously defined,  
 R 11  is H or OH,  
 R 12  is H, COOH, CO 2 R C  where R C  is as previously defined, or CONHR E  where R E  is as previously defined,  
 R 13  is OH, OR B  where R B  is as previously defined, or COR A  where R A  is as previously defined,  
 R 14  is H, or COR A  where R A  is as previously defined,  
 R 15  is COR A  where R A  is as previously defined,  
 R 16  is H, COR B  or CO 2 R C  where R B  and R C  are as previously defined,  
 R 17  is H or hydroxy C 1-10  alkyl,  
 R 18  is H or C 1-10  alkyl,  
 and “ ” represents either a single bond or a double bond.  
 
     
     
         12 . A process for the manufacture of a medicament for the treatment, amelioration, prophylaxis and/or prevention of UV induced immunosuppression in the skin, and UV induced skin disorders, which process comprises providing an extract of soy or clover and blending said extract with one or more dermatologically acceptable carriers so as to provide a dermatologically acceptable composition.  
     
     
         13 . A process according to  claim 10  which further includes β-(1,3)(1,6)-glucan.  
     
     
         14 . The process according to  claim 11  wherein the compounds of Formula (I) are genistein, equol, dehydroequol, tetrahydrodaidzein, and O-desmethyl-angolensin.